

1           **Assessing the impact of SIGN 136 on opioid prescribing rates in**  
2                           **Scotland: An interrupted time series analysis**

3       Harry L. Hébert<sup>1\*</sup>, Daniel R. Morales<sup>1</sup>, Nicola Torrance<sup>2</sup>, Blair H. Smith<sup>1,3</sup>, Lesley A. Colvin<sup>1,3</sup>

4       1. Division of Population Health and Genomics, School of Medicine, Ninewells  
5       Hospital and Medical School, University of Dundee, Dundee, UK.

6       2. School of Nursing, Midwifery & Paramedic Practice, Robert Gordon University,  
7       Aberdeen, UK.

8       3. Joint senior authors

9

10    **\*Corresponding author:** Harry L. Hébert, Ph.D.

11    Chronic Pain Research Group

12    Division of Population Health and Genomics

13    Mackenzie Building

14    Ninewells Hospital and Medical School

15    Kirsty Semple Way

16    Dundee

17    DD2 4BF

18

19    **Tel:** +44 (0)1382 383191

20    **Email:** [h.hebert@dundee.ac.uk](mailto:h.hebert@dundee.ac.uk)

21

22    **Keywords:** Opioid, prescribing, interrupted time series analysis, SIGN 136

## 1 **Abstract**

2 **Background:** Opioids are used to treat patients with chronic pain, but their long-term  
3 use is associated with harms. In December 2013, SIGN 136 was published, providing  
4 a comprehensive evidence-based guideline for the assessment and management of  
5 chronic pain in Scotland

6 **Aims:** This study aimed to examine the impact of SIGN 136 on opioid prescribing  
7 trends and costs across the whole of Scotland.

8 **Methods:** Opioid prescribing data and average cost per item were obtained from  
9 Public Health Scotland. An interrupted time series analysis examined the effects of  
10 SIGN 136 publication on the number of items prescribed per 1,000 population per  
11 quarter for 29 opioids (or opioid-containing combinations) from 2005 to 2019 inclusive.  
12 Exploratory analysis was conducted in NHS Tayside and NHS Fife combined and then  
13 up-scaled to all 14 NHS Scotland health boards. A similar approach was also used to  
14 assess the effect of SIGN 136 on estimated gross ingredient costs per quarter.

15 **Results:** At six years post-intervention there was a relative reduction in opioid  
16 prescribing of 18.8% (95% CI: 16.0-21.7) across Scotland. There was also a relative  
17 reduction of 22.8% (95%: 14.9-30.1) in gross ingredient cost nationally. Opioid  
18 prescribing increased significantly pre-intervention across all 14 NHS Scotland health  
19 boards (2.19 items per 1000 population per quarter), followed by a non-significant  
20 change in level and a significant negative change in trend post-intervention (-2.69  
21 items per 1000 population per quarter). Similar findings were observed locally in NHS  
22 Tayside and NHS Fife.

23 **Conclusions:** The publication of SIGN 136 coincided with a statistically significant  
24 reduction in opioid prescribing rates in Scotland and suggests that changes in clinical  
25 policy are having a positive effect on prescribing practices in primary care. These  
26 prescribing trends appear to be in contrast to the UK as a whole.

## 1 **Background**

2 Chronic pain is a common and complex problem, which has a debilitating impact on  
3 quality of life (James et al., 2018). The disorder affects approximately 13-50% of  
4 adults in the UK and whilst there is no cure, opioids are commonly used to treat  
5 patients with acute and malignant chronic pain (Mills et al., 2019). There is good  
6 evidence of their efficacy in this regard, but their effectiveness for long-term chronic  
7 pain is less clear (Chou et al., 2015, Moore et al., 2015). Added to this, tolerance can  
8 occur in some patients, leading to escalation to higher doses (Dumas and Pollack,  
9 2008). Both long-term and high-dose opioid use are associated with adverse events  
10 such as dependence, addiction, overdose and death (Chou et al., 2015, Higgins et al.,  
11 2018, 2019).

12 Opioid use has been increasing steadily worldwide with The World Drug Report –  
13 2020 estimating that 57.8 million people used opioids globally in 2018 (United Nations,  
14 2020). In particular, the increase in prescribing of opioids in the USA from the late  
15 1990s to the early 2010s has been well documented (Centers for Disease Control and  
16 Prevention (CDC), 2011), with 9.9 million people aged 12 years or over reported to  
17 have misused prescription opioids (United Nations, 2020). There are a number of  
18 possible explanations for this increase in opioid use, including an ageing population at  
19 greater risk of developing chronic pain conditions, changes in prescribing  
20 recommendations with increased use for chronic non-cancer pain and more effective  
21 marketing from pharmaceutical companies (Smith et al., 2019). This increase in opioid  
22 use has given rise to the “opioid epidemic” in the USA and there are concerns a  
23 similar situation could be happening in Scotland (Dhalla et al., 2011, Kimber et al.,  
24 2019). For example, an 18-fold increase in the rate of strong opioid prescribing was  
25 identified in NHS Tayside between 1995 and 2010 (Ruscitto et al., 2015).

26 In December 2013, the Scottish Intercollegiate Guideline Network (SIGN) in  
27 consultation with the National Chronic Pain Steering Group of the Scottish  
28 Government published a comprehensive evidence-based guideline for the  
29 assessment and management of non-malignant chronic pain (SIGN 136)(Scottish  
30 Intercollegiate Guideline Network, 2013). SIGN 136 remains the only comprehensive  
31 guideline for chronic pain assessment and management available globally and  
32 identified a research gap around understanding rates and effects of opioid prescribing  
33 in Scotland. A resulting investigation of national data revealed that prescribing rates of  
34 strong opioids doubled in the 10-year period leading up to publication of SIGN 136  
35 (2003-2012) and that approximately 18% of the population were prescribed an opioid  
36 in 2012 (Torrance et al., 2018). This increase appears to be replicated in the rest of  
37 the UK (Jani et al., 2020).

38 Opioid prescribing rates have now become one of NHS Scotland’s key National  
39 Therapeutic indicators, but to the best of our knowledge, opioid prescribing rates in  
40 Scotland have not been formally investigated since the publication of SIGN 136.  
41 However, there is anecdotal evidence that they are beginning to fall. Therefore this  
42 study aimed to examine the potential impact of SIGN 136 on opioid prescribing trends  
43 and costs across the whole of Scotland.

## 1 **Methods**

2

### 3 **Study Design**

4 The National Health Service (NHS) in Scotland is administered through 14 regional  
5 Health Boards. The study design is an interrupted time series analysis across 15 years  
6 of NHS health board level prescribing data on opioid analgesics. Initially, local data  
7 were obtained for NHS Tayside and NHS Fife to conduct an exploratory analysis, as  
8 the senior authors from the University of Dundee (L.A.C. and B.H.S.) have been  
9 involved in developing pathways for chronic pain management based on the SIGN  
10 136 guideline in these areas. Following this preliminary analysis, further national-level  
11 data were obtained across all 14 Health Boards, to examine whether the results  
12 obtained locally were replicated across the whole of Scotland. As of 2019, the mid-  
13 year population estimate was 791,020 for NHS Tayside and NHS Fife combined and  
14 5,463,300 across the whole of Scotland.

15 The data used in this study contained no patient or prescriber identifiable information.  
16 HIC Standard Operational Procedures have been approved by both the Caldicott  
17 Guardian and NHS Tayside Research Ethics Committee and review of individual  
18 studies is not required provided that only anonymized data are used and HIC  
19 Standard Operational Procedures are followed.

20

### 21 **Data Source**

22 Data on opioids prescribed through primary care and dispensed by community  
23 pharmacists in Scotland were obtained through the Health Informatics Centre,  
24 University of Dundee for NHS Tayside and NHS Fife and from Public Health Scotland  
25 for the national-level data (PHS; formerly the Information Services Division), via a  
26 bespoke data request. PHS is part of NHS Scotland  
27 (<https://www.publichealthscotland.scot/>) and holds individual-level prescribing data  
28 through the Prescribing Information System (PIS), which is a data system, set up in  
29 2009, of prescriptions dispensed and reimbursed in the community, covering  
30 approximately 5.3 million residents across Scotland (Alvarez-Madrado et al., 2016).

31

### 32 **Intervention**

33 The National Chronic Pain Steering Group in conjunction with the Scottish  
34 Government and work from key stakeholders, identified a gap in the clinical guidance  
35 of managing chronic pain. This work was taken to SIGN with a proposal to produce  
36 recommendations on the assessment and management of chronic pain. SIGN  
37 develops guidelines based on rigorous systematic reviews and appraisals of evidence  
38 specifically for the NHS in Scotland. Subsequently, SIGN 136 was published in  
39 December 2013. The opioids section of this guideline (section 5.3 "Opioids"), was  
40 subsequently updated in August 2019. However for this study we only considered the  
41 original 2013 publication as the intervention. This included key recommendations and  
42 best practices on safe and effective opioid prescribing (Box 1). This includes

1 considering the use of “strong opioids” for patients with chronic low back pain or  
2 osteoarthritis, with regular review required and specialist referral if there are concerns  
3 about rapid-dose escalation or if greater than 180 mg/day (subsequently updated to  
4 90mg/day in the 2019 revised edition) morphine equivalent dose is required (Scottish  
5 Intercollegiate Guideline Network, 2013). The Scottish Government requires Health  
6 Boards to identify areas of concern where they are not meeting SIGN’s Key  
7 recommendations, so they become important benchmark standards for care. SIGN  
8 136 has formed the basis of pain service provision and improvement in Scotland since  
9 its publication, and is assumed as the intervention in this study.

10

## 11 **Outcome**

12 The primary outcome was the number of opioid items dispensed per quarter per 1000  
13 population. Quarters were defined as January to March (Q1), April to June (Q2), July  
14 to September (Q3) and October to December (Q4), inclusive. A list of the 29 drugs  
15 included in the study (consisting of single opioids and compound or combination  
16 analgesics including an opioid) is given in box 2. These include drugs found in chapter  
17 4.7.2 (“opioid analgesics”) of the British National Formulary (BNF) (Joint Formulary  
18 Committee, 2020). The dataset includes all items prescribed through primary care and  
19 dispensed in Scotland. Information on items prescribed but not subsequently  
20 dispensed is not currently held by PHS. Items prescribed in Scotland and dispensed in  
21 England, private prescriptions, hospital and direct supply of medicines to patients (e.g.  
22 prescriptions supplied through clinics) were excluded.

23 The secondary outcome was the gross ingredient cost for opioid items dispensed per  
24 quarter.

25

## 26 **Statistical Analysis**

27 In the primary analysis, an interrupted time series with segmented regression was  
28 used to examine the impact of SIGN 136 on prescribing trends both locally and  
29 nationally between Q1 2005 and Q4 2019, inclusive. The segmented regression used  
30 the following model:

$$Y = \beta_0 + \beta_1 * Time + \beta_2 * Intervention + \beta_3 * Intervention * Time$$

31 Where  $Y$  is the outcome (prescribing rate or cost),  $\beta_0$  is the intercept representing the  
32 value of the outcome at the start of the study period,  $\beta_1$  represents the change in  
33 outcome per unit time (quarter) before the intervention,  $\beta_2$  represents the immediate  
34 step change in level following the intervention and  $\beta_3$  represents the change in trend  
35 following the intervention (relative to the baseline trend). Time and intervention relate  
36 to variables representing the time elapsed since the start of the study period and the  
37 pre- or post-study period, respectively.

38 The intervention was defined as Q4, 2013, providing 36 data points before the  
39 intervention and 24 data points after the intervention.

1 The secondary analysis used a similar approach to examine the impact of SIGN 136  
2 on gross ingredient cost nationally between Q1 2005 and Q4 2019, inclusive. Data on  
3 the average gross ingredient cost per item for each drug were obtained through the  
4 annual publication of prescription cost analysis report from PHS  
5 (<https://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Community-Dispensing/Prescription-Cost-Analysis/>). This was multiplied by the number of items  
6 for each drug per quarter.  
7

8 For each regression analysis the following were estimated:

- 9 • the trend before the intervention
- 10 • the immediate step change following implementation of the intervention
- 11 • the change in trend following implementation of the intervention

12 The effect of the intervention was calculated from the model coefficient estimates by  
13 subtracting the expected value of the outcome, had the pre-intervention trend  
14 continued, from the observed value of the outcome at quarter 4, 2019. The effects are  
15 presented as relative percentage changes and 95% confidence intervals (CI) were  
16 calculated using model bootstrapping approaches (Zhang et al., 2009). All models  
17 were checked for autocorrelation using the Durbin-Watson statistic.

18 All analyses were carried out using the statistical software R (version 4.0.3; R Core  
19 Team, 2020).

## 1 Results

2

### 3 Prescribing Rates

4 Between Q1 2005 and Q4 2019, a total of 91,210,542 prescription items were  
5 dispensed across Scotland for the 29 drugs included in this study. The most  
6 commonly prescribed drugs were co-codamol (40,099,832 items; 44.0% of total),  
7 tramadol (14,350,361 items; 15.7%), co-dydramol (7,430,818 items; 8.1%),  
8 dihydrocodeine (7,200,128 items; 7.9%), methadone (7,184,903 items; 7.9%),  
9 morphine (5,554,778 items; 6.1%), oxycodone (2,717,417 items; 3.0%), codeine  
10 (2,297,259 items; 2.5%), fentanyl (1,361,855 items; 1.5%), and buprenorphine  
11 (1,215,554 items; 1.3%). Co-codamol and tramadol (54,450,193 items; 59.7%) had  
12 more prescription items dispensed across the study period than the rest of the 27  
13 drugs combined (36,760,349 items; 40.3%).

14 In NHS Tayside and NHS Fife combined, the overall number of opioid prescription  
15 items rose steadily from 135,045 in Q1 2005 to 214,557 in Q4 2013. Since the  
16 publication of SIGN 136, the number of opioid prescriptions has gradually fallen to  
17 210,604 items (Figure 1A). The interrupted time series analysis of this data showed a  
18 statistically significant positive trend in the prescribing rate leading up to the  
19 intervention (2.17 items per 1,000 population per quarter, 95% CI: 1.97, 2.38),  
20 followed by an immediate, non-significant fall and a significant negative change in  
21 trend following the intervention (-2.68 items per 1,000 population per quarter, 95% CI:  
22 -3.12, -2.25). There was a significant negative post-intervention trend (-0.50 items per  
23 1,000 population per quarter, 95% CI: -0.86, -0.15) and at the end of the study period  
24 the observed quarterly opioid prescribing rate was estimated to be 20.2% lower (95%  
25 CI: 17.5, 23.1) than the expected rate had the pre-intervention trend continued (Table  
26 2A).

27 Across the whole of Scotland, the number of opioid prescription items also rose  
28 steadily from 1,040,276 in Q1 2005 to 1,608,984 in Q4 2013. Since the publication of  
29 SIGN 136, the number of opioid prescriptions has gradually fallen to 1,596,240 items  
30 (Figure 1B). The interrupted time series analysis of this data showed a statistically  
31 significant positive trend in the prescribing rate before the intervention (2.19 items per  
32 1,000 population per quarter, 95% CI: 1.97, 2.40), followed by an immediate non-  
33 significant fall, and a significant negative change in trend following the intervention (-  
34 2.69 items per 1,000 population per quarter, 95% CI: -42.20, -29.76). There was a  
35 significant negative post-intervention trend (-0.50 items per 1,000 population per  
36 quarter, 95% CI: -0.88, -0.13) and at the end of the study period the observed  
37 quarterly opioid prescribing rate was estimated to be 18.8% lower (95% CI: 16.0, 21.7)  
38 than the expected rate had the pre-intervention trend continued (Table 2B).

39

### 40 Costs

41 Between Q1 2005 and Q4 2019, the estimated total gross ingredient cost of opioid  
42 prescription items dispensed across Scotland for the 29 drugs included in this study  
43 was £849,786,655. The drugs with the highest estimated total gross ingredient cost



1 were co-codamol (£223,618,648; 26.3%), oxycodone (£106,511,546; 12.5%),  
2 methadone (£96,207,292; 11.3%), tramadol (£89,783,312; 10.6%), fentanyl  
3 (£75,532,220; 8.9%), co-dydramol (£64,225,466; 7.6%), morphine (£53,398,259;  
4 6.3%), buprenorphine (£41,016,450; 4.8%), dihydrocodeine (£36,030,814; 4.2%), and  
5 buprenorphine and naloxone (£25,796,014; 3.0%). Co-codamol, oxycodone and  
6 methadone (£426,337,486; 50.2%) had a higher estimated gross ingredient cost  
7 across the study period than the rest of the 26 drugs combined (£423,449,169;  
8 49.8%).

9 Across the whole of Scotland, the estimated gross ingredient cost for the 29 drugs  
10 rose from £9,722,763 in Q1 2005 to £14,693,703 in Q4 2013. Since the publication of  
11 SIGN 136, the estimated gross ingredient cost has gradually fallen to £13,735,668 in  
12 Q4 2019 (Figure 1C). The interrupted time series analysis of this data showed a  
13 statistically significant positive trend in cost before the intervention (£78,473 per  
14 quarter, 95% CI: 48,653, 108,291), followed by an immediate non-significant rise, and  
15 a significant negative change in trend following the intervention (£-193,044 per  
16 quarter, 95% CI: -255,438, -130,649). There was a significant negative post-  
17 intervention trend (£-114,571 per quarter, 95% CI: -161,969, -67,175) and at the end  
18 of the study period the observed gross ingredient cost was estimated to be 22.8%  
19 lower (95% CI: 14.9, 30.1) than the expected gross ingredient cost had the pre-  
20 intervention trend continued (Table 2C).



## 1 Discussion

2 In this study, we found that the publication of SIGN 136 coincided with a statistically  
3 significant reduction of 20.2% in primary care prescribing of opioids locally in NHS  
4 Tayside and NHS Fife combined at the end of the study period. This finding was  
5 replicated at a national level, with the intervention coinciding with a statistically  
6 significant reduction of 18.8% in opioid prescribing. Over 90 million prescription items  
7 were dispensed for the 29 opioid or opioid combinations across Scotland in the 15-  
8 year study period. Co-codamol and tramadol were the most prescribed drugs and had  
9 more items dispensed than the other 27 drugs combined. Additionally the publication  
10 of SIGN 136 was associated with a significant reduction of 22.8% in the gross  
11 ingredient cost of the drugs included in the study, with co-codamol, oxycodone and  
12 methadone having the highest costs in the 15-year period and having a higher  
13 combined cost than the other 26 drugs. However, caution should be exercised with  
14 respect to this model as the plot suggests there could be a non-linear relationship both  
15 before and after the intervention (a key assumption of linear regression analysis). This  
16 requires further investigation. To the best of our knowledge this is the first study to  
17 analyse changes in opioid prescribing costs in Scotland.

18 The increase in opioid prescribing up to 2013, both locally and nationally, has been  
19 described in previous studies conducted in Scotland. Ruscitto and colleagues  
20 identified an 18-fold increase in the rate of strong opioid prescribing in NHS Tayside  
21 between 1995-2010 and Torrance and colleagues found that strong opioids doubled  
22 from 2003 to 2012 and weak opioids increased by ~50% (Ruscitto et al., 2015,  
23 Torrance et al., 2018). However, both of these studies were conducted before the  
24 publication of SIGN 136. A more recent study by Jani and colleagues showed similar  
25 increases in the UK as a whole with a 30-fold, 7-fold and 5 fold increase in oxycodone,  
26 tramadol and codeine prescriptions respectively between 2006 and 2017 (Jani et al.,  
27 2020). This continuing increase in opioid prescribing across the UK beyond 2013 and  
28 the publication of SIGN 136, appears to be in contrast with the results from this  
29 Scottish study.

30 In common with all epidemiological studies, association does not necessarily mean  
31 causation and the impact of other interventions and processes cannot be ruled out.  
32 SIGN 136 has been influential in driving government policy on chronic pain  
33 management and has been incorporated into clinical practice with the publication of  
34 the National Prescribing Strategy for Chronic Pain (Scottish Government Effective  
35 Prescribing and Therapeutics Branch, 2018), the Royal College of Anaesthetists  
36 Quality Improvement Compendium (The Royal College of Anaesthetists, 2020) and  
37 the Medicines and Healthcare products Regulatory Agency guidance on the safe use  
38 of opioids (Medicines and Healthcare products Regulatory Agency, 2020). Coverage  
39 of the ongoing opioid epidemic in the USA and elsewhere in the world through the  
40 press is also likely to have raised awareness amongst the general public and patients  
41 with chronic pain may have gained a greater understanding of the risks of opioid  
42 treatments and other options available. An update to SIGN 136 was also published in  
43 August 2019, providing more specific and detailed guidance on opioid prescribing  
44 (Scottish Intercollegiate Guideline Network, 2019). The potential impact of this update  
45 has yet to be realised and should be the focus of future studies.

1 A strength of the study is the number of data points available before and after the  
2 intervention. We had 36 data points pre-intervention and 24 data points post-  
3 intervention, which meant that the study was able to identify a significant change in  
4 trend in both the prescribing rate and estimated costs. Another strength of the study is  
5 the coverage in community prescribing. GPs account for approximately 95% of  
6 community prescribing and so the dataset that was provided by PHS is a  
7 comprehensive representation of the overall state of opioid prescribing in Scotland  
8 (Alvarez-Madrado et al., 2016).

9 A limitation of the PIS database that PHS uses is that it does not currently capture  
10 prescriptions that are not dispensed or claimed by a pharmacist in Scotland (Alvarez-  
11 Madrazo et al., 2016). However, the proportion of these is likely to be very small.

12 The study was also able to analyse a large number of opioids and opioid combinations  
13 and future work will focus on separating the drugs into 'strong' and 'weak' opioids, in  
14 line with previous studies.

15 Due to the preliminary nature of this analysis, further work will be conducted to  
16 improve the models developed so far. In particular, the effects of age, gender and  
17 social deprivation will be explored. Models will also be corrected to take into account  
18 seasonality, autocorrelation (the tendency for observations close to each other in time  
19 to be more similar than observations further apart in time) and a possible delay in the  
20 intervention effect.

21 In conclusion, opioid prescribing rates and costs are falling in Tayside, Fife and across  
22 Scotland. Whilst this effect cannot be definitively linked to the publication of SIGN 136,  
23 it at least suggests that changes in clinical and government policy, most of which have  
24 been inspired by its publication, are having a positive effect on prescribing practices in  
25 primary care. This highlights the importance of providing continued sound clinical  
26 advice, based on up-to-date evidence, for safe and effective treatment for chronic  
27 pain. This process will continue as further guidelines are published.

28

1 **Acknowledgements**

2 We acknowledge the help and support of Public Health Scotland and the Health  
3 Informatics Centre, University of Dundee for managing and supplying the anonymised  
4 data.

5

6 **Funding**

7 No external financial support was received for this study.

8

9 **Conflict of Interest**

10 L.A.C. chaired the Guideline Development Group for the Scottish Intercollegiate  
11 Guideline Network publication, "Management of Chronic Pain" to which this paper  
12 refers, proposed an update due to changing evidence, and contributed to the update  
13 of the opioids section. She has been Vice Chair of SIGN since October 2020 and was  
14 a member of the Scottish Government group that developed the Quality Prescribing  
15 Strategy for Chronic Pain.

16 B.H.S. was a member of the Guideline Development Group for the Scottish  
17 Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which  
18 this paper refers. He is the Scottish Government's National Lead Clinician for Chronic  
19 Pain (since 2014).

20 D.R.M. is supported by a Wellcome Trust Clinical Research Development Fellowship  
21 (Grant 214588/Z/18/Z) and reports grants from the Chief Scientist Office (CSO),  
22 Health Data Research UK (HDR-UK) and the National Institute of Health Research  
23 (NIHR), outside of the submitted work.

24 H.L.H., and N.T. have no conflicts of interest to disclose.

25

26

Box 1 – Summary of the original SIGN 136 guideline (2013 edition) intervention for use of opioids in the management of adults with chronic non-malignant pain in non-specialist settings

**Key recommendation(s)** (based on evidence)

- Strong opioids should be considered as an option for pain relief for patients with chronic low back pain or osteoarthritis, and only continued if there is ongoing pain relief. Regular review is required.

**Other recommendation(s)** (based on evidence)

- Patients prescribed opioids should be advised of the likelihood of common side effects such as nausea and constipation.
- It may be necessary to trial more than one opioid sequentially, as both effectiveness and side effects vary between opioids.
- Signs of abuse and addiction should be sought at re-assessment of patients using strong opioids. Routine urine drug testing, pill counts or prescription monitoring should not be used to detect problem use.
- Currently available screening tools should not be relied upon to obtain an accurate prediction of patients at risk of developing problem opioid use before commencing treatment.
- Specialist referral or advice should be considered if there are concerns about rapid-dose escalation with continued unacceptable pain relief, or if >180 mg/day morphine equivalent dose is required.

**Good Practice Points** (based on clinical experience of the guideline development group)

- All patients on strong opioids should be assessed regularly for changes in pain relief, side effects and quality of life, with consideration given to a gradual reduction to the lowest effective dose.
- Opioid rotation should be considered for chronic pain that is likely to respond to opioids, if there are problems with efficacy or side effects.
- There should be careful assessment of pre-existing risk factors for developing opioid misuse. In patients where opioid therapy is indicated, but there is an increased risk of iatrogenic opioid misuse, specialist advice should be sought. The minimal effective dose should be used to avoid increased problems of fracture and overdose that may occur on higher doses.

Box 2 – List of opioids (BNF 4.7.2) and opioid-containing combination analgesics included in the study

<b>Single opioids</b>	<b>Opioid-containing combination</b>
<ul style="list-style-type: none"><li>• Buprenorphine</li><li>• Codeine phosphate</li><li>• Diamorphine hydrochloride</li><li>• Dihydrocodeine tartrate</li><li>• Fentanyl</li><li>• Hydromorphone hydrochloride</li><li>• Meptazinol</li><li>• Methadone hydrochloride</li><li>• Morphine</li><li>• Oxycodone</li><li>• Papaveretum</li><li>• Pentazocine</li><li>• Pethidine hydrochloride</li><li>• Tapentadol</li><li>• Tramadol hydrochloride</li></ul>	<ul style="list-style-type: none"><li>• Aspirin with papaveretum</li><li>• Buprenorphine and naloxone</li><li>• Chloroform and morphine</li><li>• Co-codamol</li><li>• Co-codamol with buclizine hydrochloride</li><li>• Co-codaprin</li><li>• Co-dydramol</li><li>• Dipipanone with cyclizine</li><li>• Ibuprofen with codeine phosphate</li><li>• Morphine with cyclizine</li><li>• Oxycodone and naloxone</li><li>• Paracetamol with tramadol hydrochloride</li><li>• Paracetamol, codeine &amp; caffeine</li><li>• Pethidine with promethazine</li></ul>

Mid-year population estimate (n)	Region	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
	A. NHS Tayside and NHS Fife	748,460	752,500	757,120	761,950	765,790	769,680	775,550	777,950	779,060	781,050	783,120	785,800	787,500	787,990	791,020
	B. Scotland	5,110,200	5,133,000	5,170,000	5,202,900	5,231,900	5,262,200	5,299,900	5,313,600	5,327,700	5,347,600	5,373,000	5,404,700	5,424,800	5,438,100	5,463,300

Table 1 – Mid-year population estimates for NHS Tayside and NHS Fife combined and all 14 NHS Scotland health boards combined

Table 2 – Results of the interrupted time series analysis of opioid prescribing data and costs from NHS Tayside and NHS Fife combined and across Scotland

Models	Intercept, $\beta$ (95% CI)	Pre-intervention trend, $\beta$ (95% CI / SE)	Change in level, $\beta$ (95% CI / SE)	Change in trend, $\beta$ (95% CI / SE)	Post-intervention trend, $\beta$ (95% CI / SE)	Relative Intervention Effect, % (95% CI) <sup>a</sup>
<b>Prescribing Rate</b>						
<b>A. NHS</b>	197.44	2.18	-1.80	-2.68	-0.50	20.2
Tayside and NHS Fife	(193.03, 201.85) <sup>□</sup>	(1.97, 2.38 / 0.10) <sup>□</sup>	(-8.70, 5.10 / 3.45)	(-3.12, -2.25 / 0.22) <sup>□</sup>	(-0.86, -0.15 / 0.17) <sup>□</sup>	(17.5-23.1)
<b>B. Scotland</b>	224.46	2.19	-2.26	-2.69	-0.50	18.8
	(219.83, 229.08) <sup>□</sup>	(1.97, 2.40 / 0.11) <sup>□</sup>	(-9.50, 4.98 / 3.61)	(-3.15, -2.23 / 0.23) <sup>□</sup>	(-0.88, -0.13 / 0.18) <sup>□</sup>	(16.0-21.7)
<b>Cost</b>						
<b>C. Scotland</b>	12,443,130	78,473	729,474	-193,044	-114,571	22.8
	(11,810,455, 13,075,803) <sup>□</sup>	(48,653, 108,291 / 14,885) <sup>□</sup>	(-261,260, 1,720,208 / 494,566)	(-255,438, -130,649 / 31147) <sup>□</sup>	(-161,969, -67,175 / 22,854) <sup>□</sup>	(14.9-30.1)

<sup>□</sup>P < 0.05

$\beta$ , coefficient; CI, confidence interval; NHS, National Health Service; SE, standard error

<sup>a</sup>95% Confidence Interval calculated using model bootstrapping






Figure 1 – Plots of the opioid prescribing rate and costs locally and across Scotland from Q1 2005 to Q4 2019. **A.** The prescribing rate of opioids in NHS Tayside and NHS Fife combined. **B.** The prescribing rate of opioids in all 14 NHS Scotland health boards. **C.** The gross ingredient cost of opioids across all 14 NHS Scotland health boards. The red dotted line represents the publication of SIGN 136 (Q4 2013). The solid black lines represents the trend derived from the segmented regression.

## References

- Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M. Data Resource Profile: The Scottish National Prescribing Information System (PIS). *Int J Epidemiol* 2016;45(3):714-5f.
- Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. *MMWR Morb Mortal Wkly Rep* 2011;60(43):1487-92.
- Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med* 2015;162(4):276-86.
- Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis. *BMJ* 2011;343:d5142.
- Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. *AAPS J* 2008;10(4):537-51.
- Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. *Br J Anaesth* 2018;120(6):1335-44.
- Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. *Br J Anaesth* 2019;122(6):e114-e26.
- James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392(10159):1789-858.
- Jani M, Birlie Yimer B, Sheppard T, Lunt M, Dixon WG. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. *PLoS Med* 2020;17(10):e1003270.
- Joint Formulary Committee. *British National Formulary* (online) London: BMJ Group and Pharmaceutical Press. 2020. <http://www.medicinescomplete.com>
- Kimber J, Hickman M, Strang J, Thomas K, Hutchinson S. Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis. *Lancet Psychiatry* 2019;6(8):639-40.
- Medicines and Healthcare products Regulatory Agency. Opioids: risk of dependence and addiction. 2020. <https://www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction>
- Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *Br J Anaesth* 2019;123(2):e273-e83.
- Moore RA, Derry S, Aldington D, Wiffen PJ. Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. *Cochrane Database Syst Rev* 2015;2015(10):Cd011407.
- R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. <https://www.R-project.org/>
- Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. *Eur J Pain* 2015;19(1):59-66.

- Scottish Government Effective Prescribing and Therapeutics Branch. The Scottish Chronic Pain Prescribing Strategy. 2018. <https://www.therapeutics.scot.nhs.uk/pain/>
- Scottish Intercollegiate Guideline Network. SIGN 136. Management of chronic pain: a national clinical guideline. 2013. <https://www.sign.ac.uk/assets/sign136.pdf>
- Scottish Intercollegiate Guideline Network. SIGN 136: management of chronic pain: a national clinical guideline (revised edition). 2019. [https://www.sign.ac.uk/media/1108/sign136\\_2019.pdf](https://www.sign.ac.uk/media/1108/sign136_2019.pdf)
- Smith BH, Fletcher EH, Colvin LA. Opioid prescribing is rising in many countries. *BMJ* 2019;367:l5823.
- The Royal College of Anaesthetists. Raising the Standards: RCoA quality improvement compendium. 2020. [https://rcoa.ac.uk/sites/default/files/documents/2020-08/21075%20RCoA%20Audit%20Recipe%20Book\\_Combined\\_Final\\_25.08.2020\\_0.pdf](https://rcoa.ac.uk/sites/default/files/documents/2020-08/21075%20RCoA%20Audit%20Recipe%20Book_Combined_Final_25.08.2020_0.pdf)
- Torrance N, Mansoor R, Wang H, Gilbert S, Macfarlane GJ, Serpell M, et al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. *Br J Anaesth* 2018;120(6):1345-55.
- United Nations. World Drug Report 2020. 2020. <https://wdr.unodc.org/wdr2020/>
- Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. *J Clin Epidemiol* 2009;62(2):143-8.